GlassScriptPhysician profile
Starr L Murphy
NPI 1427712637
$1,585.12
in general payments reported to CMS, 2019-2025
13 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $371 · 2023: $306 · 2024: $389 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $237.06 | 2022-2023 | |
| Cormedix INC. | $221.42 | 2025 | Defencath |
| Incyte Corporation | $218.74 | 2022-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $201.41 | 2024 | |
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Lilly USA, LLC | $118.91 | 2025 | |
| Sanofi-Aventis U.S. LLC | $118.58 | 2021 | |
| Glaxosmithkline, LLC. | $110.84 | 2022 | |
| Amgen INC. | $68.91 | 2023 | Blincyto |
| Abbvie INC. | $62.37 | 2024 | |
| Novartis Pharmaceuticals Corporation | $60.25 | 2025 | |
| Rigel Pharmaceuticals, INC. | $21.42 | 2023 | Rezlidhia, Tavalisse |
| Siemens Medical Solutions USA, INC. | $20.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Starr Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.